1. International Diabetes Federation, IDF diabetes atlas 8th edition, http://www.diabetesatlas.org/.
2. World Health Organization, Global report on diabetes, https://www.who.int/publications/i/item/9789241565257.
3. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M., , Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract., 28,103–117 (1995).
4. Oishi M., Yamazaki K., Okuguchi F., Sugimoto H., Kanatsuka A., Kashiwagi A., Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). J Diabetes Investig., 5, 581–587 (2014).
5. Ahrén B., Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag., 9, 155–163 (2013).
6. Rossetti L., Shulman G. I., Zawalich W., Defronzo R. A., Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J. Clin. Invest., 87, 1037–1044 (1987).
7. Rossetti L. Smith D., Shulman G. I., Papachristou D., Defronzo R. A., Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest., 79, 1510–1515 (1987).
8. Wright E.M., Loo D.D., Hirayama B.A., Biology of human sodium glucose transporters. .Physiol Rev., 91, 733–94 (2011).
9. Vallon V., The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med., 66, 255–70 (2015).
10. Gallo L. A., Wright E. M., Vallon V., Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res., 12, 78–89 (2015).
11. Meng W., Ellsworth B. A., Nirschl A. A., McCann P.J., Patel M., Girotra R. N., Wu G., Sher P. M., Morrison E. P., Biller S. A., Zahler R., Deshpande P. P., Pullockaran A., Hagan D. L., Morgan N., Taylor J. R., Obermeier M. T., Humphreys W. G., Khanna A., Discenza L., Robertson J. G., Wang A., Han S., Wetterau J. R., Janovitz E. B., Flint O. P., Whaley J. M., Washburn W. N., Diabetes. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 51, 1145−1149 (2008).
12. Nomura S., Sakamaki S., Hongu M., Kawanishi E., Koga Y., Sakamoto T., Yamamoto Y., Ueta K., Kimata H., Nakayama K., Tsuda-Tsukimoto M., Discovery of Canagliflozin, a Novel C- Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. J. Med. Chem., 53, 6355−6360 (2010).
13. Eckhardt M., Himmelsbach F., Wang X-J., Sun X., Zhang L., Tang W., Krishnamurthy D., Senanayake C. H., Han Z., Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein. PCT Int. Appl. WO 2006120208, (2006).
14. Imamura M., Nakanishi K., Suzuki T., Ikegai K., Shiraki R., Ogiyama T., Murakami T., Kurosaki E., Noda A., Kobayashi Y., Yokota M., Koide T., Kosakai K., Ohkura Y., Takeuchi M., Tomiyama H., Ohta M., Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem., 20, 3263−3279 (2012).
15. Kakinuma H., Oi T., Hashimoto-Tsuchiya Y., Arai M., Kawakita Y., Fukusawa Y., Iida I., Hagima N., Takeuchi H., Chino Y., Asami J., Okumura-Kitajima L., Io F., Yamamoto D., Miyata N., Takahashi T., Uchida S., Yamamoto K., (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4- methylphenyl]-1-thio-D-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment. J. Med. Chem., 53, 3247–3261 (2010).
16. Ohtake Y., Sato T., Kobayashi T., Nishimoto M., Taka N., Takano K., Yamamoto K., Ohmori M., Yamaguchi M., Takami K., Yeu S. Y., Ahn K. H., Matsuoka H., Morikawa K., Suzuki M., Hagita H., Ozawa K., Yamaguchi K., Kato M., Ikeda S., Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. J. Med.Chem., 55, 7828−7840 (2012).
17. Bernard Z., Christoph W., John M. L., David F., Erich B., Stefan H., Michaela M., Dipl B., Theresa D., Odd E. J., Hans J. W., Uli C. B., Silvio E. I., Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med., 373, 2117–2128 (2015).
18. Bruce N., Vlado P., Kenneth W. M., Dick de Z., Greg F., Ngozi E., Wayne S., Gordon L., Mehul D., David R. M., Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med., 377, 644–657 (2017).
19. Stephen D. W., Itamar R., Marc P. B., Ofri M., Eri T. K., Avvit C., Michael G. S., Thomas A. Z., Julia F. K., Sabina A. M., Deepak L. B., Lawrence A.L., Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med., 380, 347–357 (2019).
20. Haneda M., Seino Y., Inagaki N., Kaku K., Sasaki T., Fukatsu A., Kakiuchi H., Sakai S., Samukawa Y., Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin. Ther., 38, 66–88 (2016).
21. Dyer J., Garner A., Wood I. S., Sharma A. K., Chandranath I., Shirazi-Beechey S. P., Changes in the levels of intestinal Na /glucose co-transporter (SGLT1) in experimental diabetes. Biochem Soc Trans., 25, 479S (1997).
22. Ertl P, Rohde B, Selzer P., Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties. J. Med. Chem., 43, 3714-3717 (2000).
23. Tian S., Li Y., Wang J., Zhang J., Hou T., ADME Evaluation in Drug Discovery. 9. Prediction of Oral Bioavailability in Humans Based on Molecular Properties and Structural Fingerprints. Mol. Pharmaceutics., 8, 841–851 (2011).
24. Zhou L., Cryan E. V., D'Andrea M. R., belkowski S., Conway B. R., Demarest K. T., Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J. Cell. Biochem., 90, 339–46 (2003).
25. Banerjee S. K., Mcgaffin K. R., Pator-Soler N. M., Ahmad F., SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res., 84, 111–118 (2009).
26. Hirose M., Matsushita N., Ishid N., Ibi M., Saito M., Roles of Sodium-Glucose Cotransporter 1 (SGLT1) in the Induction of Cardiac Remodeling. YAKUGAKU ZASSHI, 138, 939–943 (2018).
27. Kashiwagi Y., Nagoshi T., Yoshino T., Tanaka T., Ito K., Harada T., Takahashi H., Ikegami M., Anzawa R., Yoshimura M., Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice. Plos One, 10, 6(2015).
28. Fushimi N., Fujikura H., Shiohara H., Teranishi H., Shimizu K., Yonekubo S., Ohno K., Miyagi T., Itoh F., Shibazaki K., Tomoe M., Ishikawa-Takemura Y., Nakabayashi T., Kamada N., Ozawa T., Kobayashi S., isaji M., Structure–activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β- D-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia. Bioorg. Med. Chem., 20, 6598–6612 (2012).
29. Fushimi N., Teranishi H., Shimizu K., Yonekubo S., Ohno K., Miyagi T., Itoh F., Shibazaki K., Tomoe M., Ishikawa-Takemura Y., Nakabayashi T., Kamada N., Yamauchi Y., Kobayashi S., isaji M., Design, synthesis, and structure–activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1). Bioorg. Med. Chem., 21, 748–765 (2013).
30. Goodwin N. C., Ding Z., Harrison B. A, Stobel E. D., Harris A. L., Smith M., Thompson A. Y., Xiong W., Mseeh F., Bruce D. J., Diaz D., Gopinathan S., Li L., O’Neill E., Thiel M., Wilson A. G. E., Carson K. G., Powell D. R., Rawlins D. B., Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes. J. Med. Chem., 60, 710−721 (2017).
31. Lapuerta P., Zambrowicz B., Strumph, P., Sands A., Development of Sotagliflozin, a Dual Sodium-dependent Glucose Transporter 1/2 Inhibitor. Diabetes Vasc. Dis. Res., 12, 101−110 (2015).
32. Zambrowicz B. P., Ogbaa I., Frazier K. S., Banks P., Turnage A., Freiman J., Boehm K. A., Ruff D., Powell D. R., Sands A., Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects. Clin. Ther., 35, 1162−1773 (2013).
33. Zambrowicz B. P., Ding Z. M., Ogbaa I., Frazier K., Banks P., Turnage A., Freiman J., Smith M., Ruff D., Sands A. T., Powell D. R., Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptan on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clin. Ther., 35, 273−285 (2013).
34. Yamamoto K., Uchid S., Kitano k., Fukuhara N., Okumura-Kitajima L., Gunji E., Kozakai A., Tomoike H., Kojima N., Asami J., Toyada H., Arai M., Takahashi T., Takahashi K., TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti- hyperglycaemic activity. Br. J. Phamacol., 164, 181−191 (2011).
35. ManFred K. Frank S. Klaus G., Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes. J. Med. Chem., 41, 1007−1010 (1998).
36. Veber D. F., Johnson S. R., Cheng H., Smith B. R., Ward K. W., Kopple K. D., Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem., 45, 2615- 2623 (2002).
37. Deshpande P. P., Ellsworth B. A., Buono F. G., Pullockaran A., Singh J., Kissick T. P., Huang M- H., Lobinger H., Denzel T., Mueller R. H., Remarkable β-1-C-Arylglucosides: Stereoselective Reduction of Acetyl-Protected Methyl 1-C-Arylglucosides without Acetoxy-Group Participation., J. Org. Chem., 72, 9746−9749 (2007).
38. Mizoroki T., Mori K., Ozaki A., Arylation of Olefin with Aryl Iodide Catalyzed By Palladium. Bull. Chem. Soc. Jpn., 44, 581 (1971).
39. Heck R. F., Nolley J.P., Palladium-catalyzed vinylic hydrogen substitution reactions with aryl, benzyl, and styryl halides. J. Org. Chem., 37, 2320−2322 (1972).
40. Mohun R., Ravi K. S., Stephen D., So J. L., David W., Xue Y. H., Ferhaan A., Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J. Am. Heart. Assoc., 3, e000899 (2014).
41. Matsushita N., Ishida N., Ibi M., Saito M., Sanbe A., Shimojo H., Suzuki S., Hermann K., Takeishi Y., Morino Y., Taira E., Sawa Y., Hirose M., Chronic Pressure Overload Induces Cardiac Hypertrophy and Fibrosis via Increases in SGLT1 and IL-18 Gene Expression in Mice. Int. Heart. J., 59, 1123−1133 (2018).
42. Vicor S., Directed ortho metalation. Tertiary amide and O-carbamate directors in synthetic strategies for polysubstituted aromatics. Chem. Rev., 90, 879−933 (1990). Dess D. B., Martin J. C., Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. J. Org. Chem., 48, 4155−4156 (1983).